ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0137

Real-World Effectiveness and Immunogenicity of mRNA-1273 in Dialysis Patients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Mckeon, Katherine L., Davita Clinical Research, Minneapolis, Minnesota, United States
  • Sibbel, Scott, Davita Clinical Research, Minneapolis, Minnesota, United States
  • Luo, Jiacong, Davita Clinical Research, Minneapolis, Minnesota, United States
  • Wendt, Karl, Davita Clinical Research, Minneapolis, Minnesota, United States
  • Walker, Adam G., Davita Clinical Research, Minneapolis, Minnesota, United States
  • Lazar, Rachael, DaVita Inc, Denver, Colorado, United States
  • Zywno, Meredith L., DaVita Inc, Denver, Colorado, United States
  • Connaire, Jeffrey J., Davita Clinical Research, Minneapolis, Minnesota, United States
  • Tentori, Francesca, Davita Clinical Research, Minneapolis, Minnesota, United States
  • Young, Amy, Davita Clinical Research, Minneapolis, Minnesota, United States
  • Brunelli, Steven M., Davita Clinical Research, Minneapolis, Minnesota, United States
Background

mRNA-1273 (Moderna) is a SARS-CoV-2 vaccine that received an emergency use authorization from the US Food and Drug Administration. Clinical trials in the general population demonstrated that mRNA-1273 reduced risk of COVID-19 by 94.5%, however, dialysis patients were not represented in these trials. Here, we estimated the effectiveness and SARS-CoV-2 antibody response among real-world dialysis patients who were vaccinated with mRNA-1273.

Methods

Patients included in this analysis were adults dialyzing at a large dialysis organization. For the effectiveness analysis, patients who began an mRNA-1273 vaccination series (January-March 2021) were matched (with replacement) to up to 3 previously unvaccinated controls based on age, diabetes status, sex, race, body mass index, date of first vaccine, US state of residence, and prior known COVID-19 diagnosis. Vaccine effectiveness was estimated by calculating the hazard ratio (HR) for time to polymerase chain reaction confirmed infection between vaccinated and unvaccinated patients over 3 follow-up intervals: days 1-21, 22-42, and ≥43 after first dose of vaccine. Immunogenicity was measured in a subset of consented patients who completed the full, 2-dose mRNA-1273 vaccination schedule. Blood samples were collected approximately 28 days after the second dose of mRNA-1273, and indirect chemiluminescence immunoassays were used to measure immunoglobulin G (IgG) antibodies against SARS-CoV-2. Samples with a reading of >1 arbitrary unit (AU) were considered IgG+.

Results

We identified 23,037 patients who received mRNA-1273 and were matched to 64,243 unvaccinated controls. The HRs and 95% confidence intervals (CI) were 0.96 (0.79, 1.16), 0.51 (0.34, 0.75), and 0.27 (0.17, 0.42) during 1-21, 22-42, and ≥43 days postvaccination, respectively. Among the 329 patients with postvaccination antibody measurements, 96.0% (95% CI: 93.3%-97.9%) were IgG+ (median: 100.5 AU of IgG).

Conclusion

Our results indicate that mRNA-1273 is effective in preventing SARS-CoV-2 infection in dialysis patients. Moreover, antibodies to SARS-CoV-2 were detected in nearly all patients vaccinated with mRNA-1273 in whom antibodies were measured.